• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Unproven (Off-Label) Treatments

Unproven (Off-Label) Treatments

Background

Given the lack of approved and effective treatments for ALS, people diagnosed with the disease may seek out options that are not offered by their physician. Determining the difference between true and false information regarding ALS treatments can be difficult.

The internet has many websites that promote effective ALS treatments for purchase. Often they are well designed, boast treatments available for multiple diseases and ailments, and provide reassurance through online testimonials from previous clients. In nearly all of these cases, there is no evidence of safety and in all of them; there is no proof of benefit. Furthermore, these treatments are often extremely expensive, capitalizing on desperation and hope, and many people with ALS spend critical life savings or raise funds through family and friends for an opportunity to save their life.

Examples of such treatments include, but are not limited to; stem cell clinics, holistic/naturopathic/homeopathic/traditional medicine, and dietary or physical therapy regimens.

Resources like ALSUntangled (www.alsuntangled.com) can be valuable for balanced, open-access information about such alternative treatments and www.clinicaltrials.gov is a resource for determining whether a particular treatment is being tested in a legitimate clinical trial.

A forthcoming ALSUntangled podcast/review entitled ‘“ten red flags”-things to be wary of in alternative or off-label products’ provides helpful guide to the warning signs to look out for in an advertised potential treatment. Click here for the “ten red flags” article.

Recommendation

The SAC recommends that Alliance members defer all medical advice regarding unapproved/unproven/off-label treatments to an individual’s own clinician. This may be accompanied by objective information about the specific treatment, which may be provided by the SAC. Providing links to resources like ALSUntangled and clinical trials databases like www.clinicaltrials.gov are encouraged. Accompanying information can be especially important in situations where an individual does not have access to an ALS specialist physician and it may assist their clinician in making a medical recommendation. It can also be important to relay that there are thousands of researchers around the world who are dedicated to understanding ALS and finding effective treatments, and if there was anything, anywhere, that actually worked, we would know and we would do everything we could to get it to people living with the disease as soon as possible.

 

International Alliance of ALS/MND Associations
June 2020

 


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Eddy LeFrançois, Canada

    Eddy LeFrançois, Canada

  • Lombana, Spain

    Lombana, Spain

  • John Dinon, Australia

    John Dinon, Australia

  • Soledad Rodriguez, Spain

    Soledad Rodriguez, Spain

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • Alejandro Aquino, Argentina

    Alejandro Aquino, Argentina

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Angie Bordaen, Belgium

    Angie Bordaen, Belgium

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • Lachlan Terry, Australia

    Lachlan Terry, Australia

  • Dr. Shelly Hoover, USA

    Dr. Shelly Hoover, USA

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Olga Cosentino, Argentina

    Olga Cosentino, Argentina

  • Michel Perrozzo, France

    Michel Perrozzo, France

  • Alex, Argentina

    Alex, Argentina

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Susan Anderson, USA

    Susan Anderson, USA

  • Shaleen Latchman, Canada

    Shaleen Latchman, Canada

  • Hans Dieter Olszewski, Germany

    Hans Dieter Olszewski, Germany

  • Ann Nicol, USA

    Ann Nicol, USA

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Animesh Kumar, India

    Animesh Kumar, India

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Brian Lovell, Australia

    Brian Lovell, Australia

  • Jack Buzby, USA

    Jack Buzby, USA

  • Andrea Zicchieri, Italy

    Andrea Zicchieri, Italy
    AndreaZicchieri_conSLAncioItaly

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • David Hall, USA

    David Hall, USA

  • Laurie Petit-Jean, France

    Laurie Petit-Jean, France

  • Claudia Cominetti, Italy

    Claudia Cominetti, Italy

  • Elkin Ramiro Gaviria Muñoz, Colombia

    Elkin Ramiro Gaviria Muñoz, Colombia

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

  • Daniel Hare, USA

    Daniel Hare, USA

  • Zabun Nassar, England

    Zabun Nassar, England

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Jo Knowlton, Scotland

    Jo Knowlton, Scotland

  • Anderson Custodio Pinto, Brazil

    Anderson Custodio Pinto, Brazil

  • Christian Bär, Germany

    Christian Bär, Germany

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • John Sweeney, USA

    John Sweeney, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login